Antibody/Targeted-Drug Conjugates 2017

22-24 March 2017, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 23rd March 2017

SESSION 5:
NOVEL ALTERNATIVES

Moderator: Kendall Morrison (Genzyme Inc., Santa Monica, California, USA)

09.00-09.45
‘Exploring novel bioconjugate applications using SMARTag technology’

David Rabuka (Catalent Pharma Solutions, Somerset, New Jersey, USA)

09.45-10.15
‘Non-internalizing small molecule-drug conjugates for the treatment of solid tumors’

Samuele Cazzamalli, Alberto Dal Corso and Dario Neri (Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)

10.15-10.45
‘Aspects of targeted therapeutics’

Deryk T. Loo (Macrogenics West, South San Francisco, California, USA)

10.45-11.15
Coffee Break & Posters

SESSION 6:
ANTIBODY-DRUG CONJUGATES

Moderator: Victor Goldmacher (Cancer Targeting Solutions LLC, USA)

11.15-12.00
‘New chemical linkers for antibody-drug conjugates’

Thomas Pillow (Genentech, South San Francisco, California, USA)

12.00-12.30
‘Non-cleavable pyrrolobenzodiazepine antibody-drug conjugates’

Stephen Gregson (Spirogen-MedImmune, QMB Innovation Centre, London, UK)

12.30-13.00
Radiochemistry and immuno-PET in ADC development: Taking the fast lane

Danielle Vugts (VUMC, Amsterdam, The Netherlands)

13.00-14.00
Lunch Break & Posters

SESSION 7:
CANCER & TARGETTING

Moderator: Philip Howard (MedImmune/Spirogen Ltd, London, UK)

14.00-14.30
‘Antibody-drug conjugates for cancer therapy: Critical parameters’

Victor Goldmacher (Cancer Targeting Solutions LLC, USA)

14.30-15.00
‘Development of the ADC’s for application in gynaecological cancers’

Deyarina Gonzalez and Steven Conlan (Swansea University Medical School, Swansea, Wales, UK)

15.00-15.30
‘Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63’

Bart ECG de Goeij 1, Tom Vink 1, Hendrik ten Napel 1, Esther CW Breij 1, David Satijn 1, Richard Wubbolts 2, David Miao 3 and Paul W.H.I. Parren 1,4,5 (1 Genmab, Utrecht, The Netherlands; 2 Utrecht University, Utrecht, The Netherlands; 3 Concortis Biosystems Corp., San Diego, USA; 4 University of Southern Denmark, Odense, Denmark; 5 Leiden University Medical Center, Leiden, The Netherlands)

15.30-15.45
Tea Break & Posters

15.45-16.15
‘Sweet delivery of the bitter: Using carbohydrate-targeting antibodies for tumor-specific delivery of cytotoxic drugs’

Lars Stockl (Glycotope GmbH, Berlin, Germany)

16.15-16.45
‘HDP-101 A BCMA-targeted Amanitin-based ADC’

Andreas Pahl (Heidelberg Pharma, Ladenberg, Germany)

16.45-17.00
Moderator-led Session Discussion

SESSION 8:
PANEL DISCUSSION

17.00-17.20
‘Antibody-drug conjugates: IP considerations’
Ulrich Storz (Michalski Hüttermann Patent Attorneys, Düsseldorf, Germany)

17.20-17.40
‘IS everything already invented?’
Anwyn Dullaart (European Patent Office, Rijswijk, The Netherlands)

17.40
Discussion

 

ATDC 2017 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2017 Sponsors

  • LinXis
  • Pfizer Oncology
  • ADC Review
  • Genentech
  • NatureGeneTherapy.com
  • Sutro BioPharma
  • Oncozine
  • Genovis
  • ImmunoGen
  • Catalent
  • ONdrugDelivery
  • Cancer Targeting Solutions Consultancy
  • Aldevron
  • NBE Therapeutics
  • Lonza

ATDC 2017 Downloads

ATDC 2017 Leaflet

ATDC 2017 Mailing List

Name
E-mail Address
What is 3+2-1?